SCYX Dec 2024 2.500 call
| Previous close | 0.3400 |
| Open | 0.5500 |
| Bid | 0.5000 |
| Ask | 0.8500 |
| Strike | 2.50 |
| Expiry date | 2024-12-20 |
| Day's range | 0.5500 - 0.6000 |
| Contract range | N/A |
| Volume | |
| Open interest | 57 |
GlobeNewswireSCYNEXIS Reports First Quarter 2024 Financial Results and Provides Corporate Update
SCY-247’s IND-enabling activities continue to progress, with initiation of Phase I anticipated in the second half of 2024Clinical study reports for the FURI, CARES and NATURE trials in refractory invasive fungal infections remain on track for delivery to GSK in mid 2024, which would trigger a $10 million development milestone payment to SCYNEXISSCYNEXIS ended Q1 2024 with cash, cash equivalents and investments of $94.2 million and projects a cash runway of more than two years JERSEY CITY, N.J.,
Simply Wall St.Investors in SCYNEXIS (NASDAQ:SCYX) have unfortunately lost 87% over the last five years
Long term investing is the way to go, but that doesn't mean you should hold every stock forever. We don't wish...
- GlobeNewswire
SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 at the Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global, Formerly ECCMID)
In vivo data demonstrated efficacy of SCY-247 in mouse model of invasive candidiasis caused by Candida glabrataSCY-247 showed in vitro activity against a broad range of pathogenic fungi, including azole-resistant strains of Candida and Aspergillus species JERSEY CITY, N.J., April 30, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the presentat
